Even after treatment, CLL can return. However, advancements in monitoring are helping doctors detect relapse earlier and intervene more effectively. 

• Minimal residual disease (MRD) testing can detect one CLL cell among a million healthy cells and provides a sensitive measure of disease burden. This allows for timely intervention and treatment adjustments, potentially delaying or preventing relapse. For instance, patients achieving MRD negativity after treatment is a positive sign, often associated with better long-term outcomes. 

If optimized, regular MRD status checkups could guide therapy duration and intensity, tailoring treatment to each patient’s needs.